Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telmisartan - Boehringer Ingelheim/GlaxoSmithKline

Drug Profile

Telmisartan - Boehringer Ingelheim/GlaxoSmithKline

Alternative Names: BIBR277; Kinzal; Kinzalmono; Micardis; Pritor; PritorPlus; Telma; YM086

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Developer Abbott Laboratories; Astellas Pharma; Boehringer Ingelheim Pharma KG; GlaxoSmithKline; Glenmark Pharmaceuticals Ltd; Nippon Boehringer Ingelheim
  • Class Antihypertensives; Benzimidazoles; Benzoates; Small molecules
  • Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Essential hypertension; Hypertension
  • No development reported Metabolic syndrome
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Oct 2017 Nippon Boehringer Ingelheim and Astellas Pharma extend agreement related to the sales of telmisartan (Micardis® family) in Japan
  • 07 Jan 2016 Boehringer Ingelheim and Astellas Pharma extend agreement related to sale and co-promotion of telmisartan (Micardis® family) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top